Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
UNIGENE LABORATORIES INC (UGNE)
|
Add to portfolio |
|
|
|
| Price: |
| | Metrics |
| OS: |
96.0
|
M
| |
|
|
| Market cap: |
|
| |
|
|
|
Net debt:
|
$79.2
|
M
| |
|
|
|
EV:
|
|
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
($14.3)
|
M
| |
|
|
|
EBIT
|
($11.5)
|
M
| |
|
|
| EPS |
($0.36)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-12 | Dec-31-11 | Dec-31-10 | Dec-31-09 | Dec-31-08 | Dec-31-07 | Dec-31-06 | Dec-31-05 |
| Revenues | 9.4 | 20.5 | 11.3 | 12.7 | 19.2 | 20.4 | 6.1 | 14.3 |
| Revenue growth | -54.0% | 80.8% | -10.9% | -33.8% | -5.8% | 237.1% | -57.6% | 69.9% |
| Cost of goods sold | 1.6 | 1.6 | 2.6 | 2.2 | 5.6 | 7.2 | 1.8 | 1.4 |
| Gross profit | 7.8 | 19.0 | 8.7 | 10.6 | 13.6 | 13.2 | 4.3 | 12.8 |
| Gross margin | 82.6% | 92.4% | 77.0% | 82.9% | 70.8% | 64.6% | 71.1% | 89.9% |
| Selling, general and administrative | 8.5 | 8.9 | 7.7 | 8.9 | | | | |
| Research and development | 5.3 | 9.0 | 6.4 | 12.4 | 9.5 | | | |
| General and administrative | | | | | 7.9 | 7.8 | 6.4 | 4.6 |
| EBITA | -9.7 | -5.4 | -10.0 | -12.4 | -4.9 | -3.1 | -11.0 | 0.6 |
| EBITA margin | -102.7% | -26.1% | -88.1% | -97.2% | -25.7% | -15.2% | -181.2% | 4.2% |
| Amortization of intangibles | 0.1 | 0.1 | 0.1 | | | | | |
| EBIT | -9.8 | -5.5 | -10.1 | -12.4 | -4.9 | -3.1 | -11.0 | 0.6 |
| EBIT margin | -104.0% | -26.6% | -89.1% | -97.2% | -25.7% | -15.2% | -181.2% | 4.2% |
| Pre-tax income | -35.5 | -7.7 | -33.2 | -13.4 | -7.0 | -4.2 | -12.3 | -0.9 |
| Income taxes | -1.3 | -0.6 | -0.7 | -0.1 | -0.9 | -0.7 | -0.5 | -0.4 |
| Tax rate | 3.5% | 7.8% | 2.1% | 0.5% | 13.2% | 17.4% | 4.3% | 45.9% |
| Net income | -34.3 | -7.1 | -32.5 | 0.0 | -6.1 | -3.4 | -11.8 | -0.5 |
| Net margin | -363.3% | -34.6% | -286.9% | 0.0% | -31.6% | -16.9% | -194.5% | -3.5% |
| |
| Diluted EPS | ($0.36) | ($0.08) | ($0.35) | $0.00 | ($0.07) | ($0.04) | ($0.14) | ($0.01) |
| Shares outstanding (diluted) | 95.5 | 93.2 | 92.0 | 90.7 | 88.8 | 87.7 | 86.8 | 81.5 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|